History
  • No items yet
midpage
Delgado-Echevarria v. AstraZeneca Pharmaceuticals LP
856 F.3d 119
1st Cir.
2017
Read the full case

Background

  • Delgado worked for AstraZeneca as a Pharmaceutical Sales Specialist (hired 2001; promoted 2009) and reported a pituitary microadenoma and related biopsies to her supervisor; she later sought treatment for severe depression and anxiety and was placed on short-term disability (STD) leave beginning December 12, 2011.
  • AstraZeneca initially granted STD benefits retroactive to December 12, 2011 and extended them intermittently through April 30, 2012, but suspended/terminated benefits when it concluded Delgado had not provided adequate documentation.
  • Delgado’s psychiatrist, Dr. Sánchez, submitted various treatment records and a form indicating an estimated 12-month period of incapacity; AstraZeneca’s occupational-health reviewer concluded the documentation did not support reinstating benefits.
  • AstraZeneca sent letters warning Delgado to return to work by specified dates or be presumed to have resigned; after she did not return, AstraZeneca notified her that her termination would be effective (citing both failure to return/resignation and a reorganization that eliminated her position) and offered severance.
  • Delgado sued under the ADA and Puerto Rico law (Law 44, Article 1802, Law 80, among others). The district court granted summary judgment for AstraZeneca; Delgado appealed. The First Circuit affirms.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether Delgado was a "qualified individual" under the ADA and whether a 12‑month leave extension was a reasonable accommodation Delgado argued her psychiatrist indicated 12 months would allow recovery and that extended leave was a reasonable accommodation AstraZeneca argued Delgado could not show the requested leave was facially reasonable or that the documentation supported a return after 12 months Held for AstraZeneca: Delgado failed to show the accommodation would enable return to essential job functions or that 12 months was facially reasonable
Whether employer failed to engage in the interactive process under the ADA Delgado contended AstraZeneca did not engage in the interactive process after her leave request AstraZeneca maintained that even if it did not fully engage, Delgado failed to identify a reasonable accommodation, so no interactive-process claim survives Held for AstraZeneca: claim fails because Delgado did not show an available reasonable accommodation
Whether termination was retaliatory under the ADA Delgado argued her May 17 leave request was protected activity and termination was causally connected/retaliatory AstraZeneca offered nondiscriminatory reasons: failure to return after STD ended, presumed resignation, and elimination of position in reorganization Held for AstraZeneca: even assuming prima facie retaliation, AstraZeneca offered legitimate reasons and Delgado failed to show pretext
Whether Delgado’s Puerto Rico claims (Law 44, Article 1802, Law 80) survive independent of ADA claims Delgado sought recovery under Law 44, Article 1802 (negligence and emotional distress), and Law 80 wrongful discharge AstraZeneca argued Law 44 mirrors the ADA; Article 1802 claims duplicate ADA claims and lack independently pleaded conduct; Law 80 justified by employer’s business reasons Held for AstraZeneca: Law 44 fails with ADA; Article 1802 dismissed for lack of independent tortuous conduct and undeveloped argument; Law 80 dismissed because AstraZeneca met burden (reasonable business-based grounds) and Delgado failed to rebut pretextually

Key Cases Cited

  • Mulloy v. Acushnet Co., 460 F.3d 141 (1st Cir.) (qualified-individual element and accommodation analysis)
  • Reed v. LePage Bakeries, Inc., 244 F.3d 254 (1st Cir.) (two-part plaintiff burden: effectiveness and facial reasonableness of accommodation)
  • García-Ayala v. Lederle Parenterals, Inc., 212 F.3d 638 (1st Cir.) (leave can be reasonable; fact-specific inquiry)
  • Jones v. Nationwide Life Ins. Co., 696 F.3d 78 (1st Cir.) (summary judgment may be affirmed on any record basis; burden-shifting and reasonableness analysis)
  • Hwang v. Kan. State Univ., 753 F.3d 1159 (10th Cir.) (long leaves—e.g., six months or more—may be unreasonable accommodations)
Read the full case

Case Details

Case Name: Delgado-Echevarria v. AstraZeneca Pharmaceuticals LP
Court Name: Court of Appeals for the First Circuit
Date Published: May 2, 2017
Citation: 856 F.3d 119
Docket Number: 15-2232P
Court Abbreviation: 1st Cir.